These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 7339027)

  • 1. [Blood coagulation and glomerular nephritis].
    Hatano M; Kaizu K
    Nihon Rinsho; 1981; 39(12):3674-9. PubMed ID: 7339027
    [No Abstract]   [Full Text] [Related]  

  • 2. [Intraglomerular coagulation in patients with glomerulonephritis, with special reference to FDP D-dimer].
    Shibata T; Ura S; Hirai Y; Taura K; Harada T; Hara K
    Nihon Naika Gakkai Zasshi; 1983 Sep; 72(9):1143-9. PubMed ID: 6663183
    [No Abstract]   [Full Text] [Related]  

  • 3. [On coagulation and fibrinolysis in renal diseases, with special reference to FDP subfragment and urinary plasmin body].
    Nakamichi S
    Nihon Jinzo Gakkai Shi; 1984 Apr; 26(4):353-66. PubMed ID: 6236317
    [No Abstract]   [Full Text] [Related]  

  • 4. Fibrinogen, fibrin(ogen) degradation products and fibrinopeptide A in pleural effusions. High turnover of fibrinogen in pleurisy.
    Widström O; Kockum C; Nilsson BS
    Scand J Respir Dis; 1978 Aug; 59(4):210-5. PubMed ID: 694476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of proteases, plasminogen activators, fibrin fibrinogen degradation products and fibrinopeptides in the growth and development of neoplasms and neoplasm metastases].
    Farbiszewski R
    Postepy Hig Med Dosw; 1984; 38(2):133-55. PubMed ID: 6393101
    [No Abstract]   [Full Text] [Related]  

  • 6. Markers of fibrinogen derivatives used in clinical investigation.
    Soria J; Soria C; Mirshahi M; Samama MM
    Semin Thromb Hemost; 1985 Apr; 11(2):129-32. PubMed ID: 2412296
    [No Abstract]   [Full Text] [Related]  

  • 7. [Fibrinogen degradatiopnroducts in the serum and urine in chronic nephritis].
    Kutyrina IM; Muzychenko LI; Nevraeva OG; Kriachko AA; Tareeva IE
    Sov Med; 1978 Oct; (10):68-75. PubMed ID: 715539
    [No Abstract]   [Full Text] [Related]  

  • 8. [Blood coagulation system and fibrinolysis in glomerulonephritis (review of the literature)].
    Panchenko VM; Gilunova NI; Kozhomkulova BZh
    Lab Delo; 1977; (8):451-4. PubMed ID: 72846
    [No Abstract]   [Full Text] [Related]  

  • 9. Relationship between fibrinopeptide A and fibrinogen/fibrin fragment E in thromboembolism, DIC and various non-thromboembolic diseases.
    Mombelli G; Monotti R; Haeberli A; Straub PW
    Thromb Haemost; 1987 Aug; 58(2):758-63. PubMed ID: 3672428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in the measurement of circulating fibrinogen derivatives.
    Wilner GD
    Prog Clin Pathol; 1984; 9():15-45. PubMed ID: 6229812
    [No Abstract]   [Full Text] [Related]  

  • 11. [In vivo behavior of soluble fibrin monomer after cleavage of fibrinopeptide A].
    Müller-Berghaus G; Mahn I
    Verh Dtsch Ges Inn Med; 1978; (84):1351-3. PubMed ID: 741964
    [No Abstract]   [Full Text] [Related]  

  • 12. [Blood serum and urine levels of fibrin fibrinogen degradation products in kidney diseases].
    Kacprzyk F; Orłowski Z
    Pol Tyg Lek; 1980 Mar; 35(13):461-3. PubMed ID: 7393746
    [No Abstract]   [Full Text] [Related]  

  • 13. Deposition of fibrin-stabilizing factor (F XIIIA and S), fibrinogen-related antigens, fibrinogen degradation products (FDPd and FDPe) and antihemolytic factor (F VIII) in renal disease: analysis of 161 cases by immunofluorescence microscopy.
    Colasanti G; Morel Maroger L; D'Amico G
    Clin Nephrol; 1987 Jul; 28(1):28-34. PubMed ID: 3113791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interaction of fibrinogen with two forms of fibrin differing in the degree of activation by thrombin].
    Belitser VA; Lugovskoĭ EV; Ugarova TP; Derzskaia SG
    Biokhimiia; 1985 Aug; 50(8):1336-41. PubMed ID: 4074798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hemostatic mechanisms and malignant tumors].
    Kase F; Pospísil J; Hlousková D
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(6):809-30. PubMed ID: 2419210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunoenzyme determination of fibrinogen and its degradation products in kidney diseases].
    Maĭdannik VG
    Vrach Delo; 1989 May; (5):75-7. PubMed ID: 2672585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of low-dose heparin on fibrinopeptide A, platelets, fibrinogen degradation products and other haemostatic parameters measured in connection with intestinal surgery.
    Törngren S; Norén I; Savidge G
    Thromb Res; 1979; 14(6):871-9. PubMed ID: 382435
    [No Abstract]   [Full Text] [Related]  

  • 18. The effects of ancrod, the coagulating enzyme from the venom of Malayan pit viper (A. rhodostoma) on prothrombin and fibrinogen metabolism and fibrinopeptide A release in man.
    Bell WR; Shapiro SS; Martinez J; Nossel HL
    J Lab Clin Med; 1978 Apr; 91(4):592-604. PubMed ID: 641385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
    Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
    J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fibrin-fibrinogen degradation products in connective tissue diseases].
    Shchepotin BM; Ena IaM; Bodaretskiĭ GM
    Revmatologiia (Mosk); 1989; (2):64-8. PubMed ID: 2678401
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.